SMITHKLINE BEECHAM DEFIES DOWNTURN FOR PHARMACEUTICAL STOCKS WITH 15% GAIN IN SECOND QUARTER; GENENTECH IS RUNNER-UP, WHILE 22 OUT OF 30 ISSUES FALL

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".